Free Fatty Acid Derivative HUHS2002 Potentiates α7 ACh Receptor Responses Through Indirect Activation of CaMKII

The present study examined the effect of 4-[4-(Z)-hept-1-enyl-phenoxy] butyric acid (HUHS2002), a free fatty acid derivative, on α7 acetylcholine (ACh) receptor responses. HUHS2002 potentiated whole-cell membrane currents through α7 ACh receptors expressed in Xenopus oocytes in a concentration (1–100 nM)-dependent manner, reaching about 140 % of the original amplitude at 100 nM 50 min after a 10-min treatment. The HUHS2002 effect was prevented by KN-93, an inhibitor of Ca²⁺/calmodulin-dependent protein kinase II (CaMKII), while it was not affected by GF109203X, an inhibitor of protein kinase C (PKC), or H-89, an inhibitor of protein kinase A (PKA). In the in situ CaMKII assay using cultured rat hippocampal neurons, HUHS2002 activated CaMKII and the activation was abolished by KN-93. In the cell-free assay of protein phosphatase 1 (PP1), HUHS2002 partially inhibited PP1 activity. Taken together, these results indicate that HUHS2002 potentiates α7 ACh receptor responses by indirectly activating CaMKII, possibly via inhibition of PP1.     

Docosahexaenoic acid modulates phorbol ester-induced activation of extracellular signal-regulated kinases 1 and 2 in NIH/3T3 cells

Phosphorylation of extracellular signal-regulated kinases (ERK1/ERK2) has been implicated in cell proliferation of mammalian cells. In the present study, we investigated the role of docosahexaenoic acid (DHA) in the modulation of ERK1/ERK2 phosphorylation, stimulated either with phorbol 12-myristate 13-acetate (PMA) or transforming growth factor-alpha (TGFα) in NIH/3T3 cells. We observed that both PMA and TGFα induced ERK1/ERK2 phosphorylation within 5 min of stimulation. PMA acts upstream of MEK and via activation of protein kinase C (PKC), as GF109203X, a potent PKC inhibitor, and U0126, a MEK inhibitor, abolished its actions on ERK1/ERK2 phosphorylation. TGFα did not act via PKC because GF109203X failed to curtail the degree of ERK1/ERK2 phosphorylation in these cells. DHA alone failed to induce the phosphorylation of these mitogen-activated protein (MAP) kinases; however, this fatty acid significantly curtailed the PMA-but not TGFα-induced MAP kinase enzyme activity and phosphorylation in NIH/3T3 cells. Furthermore, we observed that DHA significantly inhibited PMA-induced translocation of two PKC isoforms, PKCα and PKCε, from cytosol to plasma membrane. Interestingly, DHA failed to inhibit the PMA-induced translocation PKCδ isoform in these cells. Furthermore, DHA decreased PMA-induced proliferation of NIH/3T3 cells. In this study, we show for the first time that DHA inhibits MAP kinase (ERK1/ERK2) activation and proliferation of NIH/3T3 cells via its inhibitory action on PKCα and ε isoforms.     

The Serine/Threonine Protein Phosphatase 2A (PP2A) Regulates Syk Activity in Human Platelets

Distinct membrane receptors activate platelets by Src-family-kinase (SFK)-, immunoreceptor-tyrosine-based-activation-motif (ITAM)-dependent stimulation of spleen tyrosine kinase (Syk). Recently, we reported that platelet activation via glycoprotein (GP) VI or GPIbα stimulated the well-established Syk tyrosine (Y)-phosphorylation, but also stoichiometric, transient protein kinase C (PKC)-mediated Syk serine(S)297 phosphorylation in the regulatory interdomain-B, suggesting possible feedback inhibition. The transient nature of Syk S297 phosphorylation indicated the presence of an unknown Syk pS297 protein phosphatase. In this study, we hypothesize that the S-protein phosphatase 2A (PP2A) is responsible for Syk pS297 dephosphorylation, thereby affecting Syk Y-phosphorylation and activity in human washed platelets. Using immunoblotting, we show that specific inhibition of PP2A by okadaic acid (OA) alone leads to stoichiometric Syk S297 phosphorylation, as analyzed by Zn²⁺-Phos-tag gels, without affecting Syk Y-phosphorylation. Pharmacological inhibition of Syk by PRT060318 or PKC by GF109203X only minimally reduced OA-induced Syk S297 phosphorylation. PP2A inhibition by OA preceding GPVI-mediated platelet activation induced by convulxin extended Syk S297 phosphorylation but inhibited Syk Y-phosphorylation. Our data demonstrate a novel biochemical and functional link between the S-protein phosphatase PP2A and the Y-protein kinase Syk in human platelets, and suggest that PP2A represents a potential enhancer of GPVI-mediated Syk activity caused by Syk pS297 dephosphorylation.     

Increased formation of phosphatidylinositol-4-phosphate in human platelets stimulated with lysophosphatidic acid

Lysophosphatidic acid (LPA, 1-acyl-sn-glycerol 3-phosphate), at a concentration of 1–40 μM, was found to induce the formation of [³H]inositol-labelled phosphatidylinositol-4-phosphate (PIP) without significantly altering the levels of either phosphatidylinositol (PI) or phosphatidylinositol bisphosphate (PIP₂) in washed human platelets. Preincubation of platelets with the cyclooxygenase/lipoxygenase inhibitor, BW755C at 100 μM, did not alter the LPA-induced formation of PIP. Activation of platelets with the phorbol ester, phorbol 12-myristate 13-acetate (PMA), elicited a similar response (induction of PIP formation). The specific protein kinase C (PKC) inhibitor, GF109203X (10 μM), completely blocked the effect of PMA but not the LPA-induced generation of PIP. The present results indicate that LPA can induce PIP formationvia PI-4-kinase activation, through processes which are independent of the eicosanoid/TxA₂ pathway and are not PKC-dependent.     

Melatonin Stimulates Dendrite Formation and Complexity in the Hilar Zone of the Rat Hippocampus: Participation of the Ca++/Calmodulin Complex

Melatonin (MEL), the main product synthesized by the pineal gland, stimulates early and late stages of neurodevelopment in the adult brain. MEL increases dendrite length, thickness and complexity in the hilar and mossy neurons of hippocampus. Dendrite formation involves activation of Ca²⁺/Calmodulin (CaM)-dependent kinase II (CaMKII) by CaM. Previous work showed that MEL increased the synthesis and translocation of CaM, suggesting that MEL activates CaM-dependent enzymes by this pathway. In this work we investigated whether MEL stimulates dendrite formation by CaMKII activation in organotypic cultures from adult rat hippocampus. We found that the CaMKII inhibitor, KN-62, abolished the MEL stimulatory effects on dendritogenesis and that MEL increased the relative amount of CaM in the soluble fraction of hippocampal slices. Also, PKC inhibition abolished dendritogenesis, while luzindole, an antagonist of MEL receptors (MT1/2), partially blocked the effects of MEL. Moreover, autophosphorylation of CaMKII and PKC was increased in presence of MEL, as well as phosphorylation of ERK1/2. Our results indicate that MEL stimulates dendrite formation through CaMKII and the translocation of CaM to the soluble fraction. Dendritogenesis elicited by MEL also required PKC activation, and signaling through MT1/2 receptors was partially involved. Data strongly suggest that MEL could repair the loss of hippocampal dendrites that occur in neuropsychiatric disorders by increasing CaM levels and activation of CaMKII.     

Structural and pharmacological characterization of phenylalanine-based AMPA receptor antagonists at kainate receptors

Continued efforts into the discovery of ligands that target ionotropic glutamate receptors (iGluRs) are important for studies of the physiological roles of the various iGluR subtypes as well as for the search for drugs that can be used in the treatment of diseases of the central nervous system. A new series of phenylalanine derivatives that target iGluRs was reported to bind AMPA receptors. Herein we report our studies of these compounds at the kainate receptors GluK1-3. Several compounds bind with micromolar affinity at GluK1 and GluK3, but do not bind GluK2. The crystal structure of the most potent compound in the ligand binding domain of GluK1 revealed different modes of binding to GluK1 and GluA2, due primarily to residues Ser741 (GluK1) and Met729 (GluA2). The compound was shown to be slightly more potent at GluK1 than at AMPA receptors and to induce a domain closure similar to that observed in GluK1 structures with partial agonists.     

Rutaecarpine Increases Nitric Oxide Synthesis via eNOS Phosphorylation by TRPV1-Dependent CaMKII and CaMKKβ/AMPK Signaling Pathway in Human Endothelial Cells

Rutaecarpine (RUT) is a bioactive alkaloid isolated from the fruit of Evodia rutaecarpa that exerts a cellular protective effect. However, its protective effects on endothelial cells and its mechanism of action are still unclear. In this study, we demonstrated the effects of RUT on nitric oxide (NO) synthesis via endothelial nitric oxide synthase (eNOS) phosphorylation in endothelial cells and the underlying molecular mechanisms. RUT treatment promoted NO generation by increasing eNOS phosphorylation. Additionally, RUT induced an increase in intracellular Ca²⁺ concentration and phosphorylation of Ca²⁺/calmodulin-dependent protein kinase kinase β (CaMKKβ), AMP-activated protein kinase (AMPK), and Ca²⁺/calmodulin-dependent kinase II (CaMKII). Inhibition of transient receptor potential vanilloid type 1 (TRPV1) attenuated RUT-induced intracellular Ca²⁺ concentration and phosphorylation of CaMKII, CaMKKβ, AMPK, and eNOS. Treatment with KN-62 (a CaMKII inhibitor), Compound C (an AMPK inhibitor), and STO-609 (a CaMKKβ inhibitor) suppressed RUT-induced eNOS phosphorylation and NO generation. Interestingly, RUT attenuated the expression of ICAM-1 and VCAM-1 induced by TNF-α and inhibited the inflammation-related NF-κB signaling pathway. Taken together, these results suggest that RUT promotes NO synthesis and eNOS phosphorylation via the Ca²⁺/CaMKII and CaM/CaMKKβ/AMPK signaling pathways through TRPV1. These findings provide evidence that RUT prevents endothelial dysfunction and benefit cardiovascular health.     

Nitrooleate Mediates Nitric Oxide Synthase Activation in Endothelial Cells

Nitrated lipids such as nitrooleate (OLA-NO₂) can act as endogenous peroxisome proliferator-activated receptor gamma (PPARγ) ligands to exert vascular protective effects. However, the molecular mechanisms regarding nitric oxide (NO) production and its regulation are not fully defined in the vasculature. Here, we show that OLA-NO₂ increased endothelial NO release by modulating activation of endothelial nitric oxide synthase (eNOS) in endothelial cells. Treatment with OLA-NO₂ (3 μM) increased NO release in a time-dependent manner. OLA-NO₂ decreased protein expression of eNOS and caveolin-1 (Cav-1) but increased heat shock protein 90 (Hsp90) expression. Immunoprecipitation analysis confirmed that OLA-NO₂ replaced eNOS/Cav-1 with eNOS/Hsp90 interaction, resulting in increasing eNOS activity. OLA-NO₂ also induced eNOS phosphorylation at Ser633 and Ser1177 and eNOS dephosphorylation at Ser113 and Thr495. In addition, OLA-NO₂ induced phosphorylation of Akt and extracellular signal-regulated protein kinase (ERK1/2), which might contribute to eNOS activation. Collectively, these results substantiate a new functional role for nitrated fatty acid, demonstrating that OLA-NO₂ exerts vascular protective effects by increasing NO bioavailability through eNOS phosphorylation/dephosphorylation and interaction with associated proteins such as Hsp90 and Cav-1.     

Novel catalyst-support interaction for direct formic acid fuel cell anodes: Pd electrodeposition on surface-modified graphite felt

The electrodeposition of Pd on graphite felt (GF, thickness ~3 mm in uncompressed state) was studied and the resulting catalyst was compared with Pt-Ru/GF for the electro-oxidation of formic acid. A micellar solution composed of the non-ionic surfactant Triton X-102 and an aqueous phase containing PdCl₂ were utilized for the galvanostatic electrodeposition of Pd nanoparticles. The presence of the surfactant during electrodeposition coupled with pretreatment of the GF surface by a Shipley-type method (PdCl₂ + SnCl₂ solution) creating nucleation sites had a major impact on the Pd catalyst morphology and penetration throughout the electrode thickness, affecting, therefore, the electrocatalytic activity toward formic acid oxidation. It was found that large (~1,000 nm) Pd particles with smooth surface favored the indirect CO_ad pathway, while Pd nanoparticles (diameter <40 nm) with rough surface, formed with surfactant and pretreatment, were much more active leading to the direct non-CO_ad pathway. Due to pretreatment the GF surface has been modified and the effective catalytic system could be described as Pd/SnO₂–Pd(PdO)/GF with possible electronic interaction between support and catalyst. In direct formic acid fuel cell (DFAFC) experiments at 333 K and 1 M HCOOH, the peak power density using the Pd/GF anode reached 852 W m^?2 (57 g m^?2 Pd) compared to 392 W m^?2 (40 g m^?2 Pd) with a commercial Pd catalyst-coated membrane (CCM). The long-term stability of Pd-based anodes was poor and inferior to Pt–Ru (4:1 at. ratio) prepared and tested under identical conditions.     

The Role of PTP1B O-GlcNAcylation in Hepatic Insulin Resistance

Protein tyrosine phosphatase 1B (PTP1B), which can directly dephosphorylate both the insulin receptor and insulin receptor substrate 1 (IRS-1), thereby terminating insulin signaling, reportedly plays an important role in insulin resistance. Accumulating evidence has demonstrated that O-GlcNAc modification regulates functions of several important components of insulin signal pathway. In this study, we identified that PTP1B is modified by O-GlcNAcylation at three O-GlcNAc sites (Ser104, Ser201, and Ser386). Palmitate acid (PA) impaired the insulin signaling, indicated by decreased phosphorylation of both serine/threonine-protein kinase B (Akt) and glycogen synthase kinase 3 beta (GSK3β) following insulin administration, and upregulated PTP1B O-GlcNAcylation in HepG2 cells. Compared with the wild-type, intervention PTP1B O-GlcNAcylation by site-directed gene mutation inhibited PTP1B phosphatase activity, resulted in a higher level of phosphorylated Akt and GSK3β, recovered insulin sensitivity, and improved lipid deposition in HepG2 cells. Taken together, our research showed that O-GlcNAcylation of PTP1B can influence insulin signal transduction by modulating its own phosphatase activity, which participates in the process of hepatic insulin resistance.     

Tuning the interlaminar shear strength and thermo-mechanical properties of glass fiber composites by incorporation of (3-mercaptopropyl) trimethoxysilane-functionalized carbon black

The incorporation of functionalized nanoscale fillers into traditional glass fiber/unsaturated polyester (GF/UPE) composites provides a more robust mechanical attributes. The current study demonstrates the potential of 3-mercaptopropyl trimethoxysilane (MPTS)-functionalized carbon black (f-CB) for enhancing the thermo-mechanical properties of GF composites. The composites infused with 1, 3 and 5 wt% of pristine and MPTS-functionalized CB were fabricated by hand lay-up and hot press processing. Tensile testing, interlaminar shear strength (ILSS) testing and dynamic mechanical analysis were used to evaluate the performance of nanocomposites. Fourier transform infrared spectroscopy validated the MPTS functionalization of CB. Pristine CB-loaded nanocomposites exhibited marginal improvement in ultimate tensile strength (UTS), ILSS and thermo-mechanical properties. However, with the addition of f-CB, the improvement in all the studied properties was more substantial. The inclusion of 5 wt% f-CB increased the elastic modulus and UTS by 16 and 22%, respectively, whereas the ILSS was enhanced by 36%, in comparison to the neat GF composite. The scanning electron microscope analysis of fractured ILSS samples revealed better fiber-matrix adhesion and compatibility in f-CB-loaded nanocomposites. At the same filler weight percentage, the storage modulus at 25 °C was ~ 19% higher than that of neat composite. The f-CB inclusion resulted in increment of T _g by ~ 13 °C over the T _g of neat GF/UPE composite (~ 109 °C). These improvements were due to the chemical connection of f-CB to the UPE matrix and GF surface. With such improvements in thermal and mechanical properties, these nanocomposites can replace the conventional GF composites with prominent improvements in performance.     

AMPK Prevents Palmitic Acid-Induced Apoptosis and Lipid Accumulation in Cardiomyocytes

Palmitic acid, a main fatty acid (FA) in human nutrition, can induce apoptosis of cardiomyocytes. However, a specific combination of palmitic, myristic and palmitoleic acid (CoFA) has been reported to promote beneficial cardiac growth. The aim of this study was to investigate the relevance of CoFA for cardiac growth and to delineate the underlying signaling pathways of CoFA and palmitic acid treatment. CoFA treatment of C57Bl/6 mice increased FA serum concentrations. However, morphologic and echocardiographic analysis did not show myocardial hypertrophy. Cell culture studies using rat ventricular cardiomyocytes revealed an increased phosphorylation of AMP activated protein kinase α (AMPKα) to 155 ± 19% and its target acetyl-CoA-carboxylase to 177 ± 23% by CoFA. Treatment with myristic acid also increased AMPKα phosphorylation to 189 ± 32%. Palmitic acid did not activate AMPKα but increased expression of the FA translocase CD36 (FAT/CD36) to 163 ± 23% and adipose-differentiation-related-protein (ADRP), a sensitive marker of lipid accumulation, to 168 ± 42%. This was associated with an increased phosphorylation of the stress-activated-protein-kinase/Jun-amino-terminal-kinase (SAPK/JNK) to 173 ± 27%. In CoFA-treated cells, phosphorylation of SAPK/JNK was unaltered. FACS analysis revealed increased apoptosis to 159 ± 5% by palmitic acid but not by CoFA. AMPK activator AICAR (5-aminoimidazole-4-carboxamide ribonucleotide) prevented up-regulation of ADRP and increased apoptosis by palmitic acid. Confirming these findings, inhibition of AMPK by compound C in CoFA-treated cardiomyocytes resulted in an increased expression of ADRP to 154 ± 27%, FAT/CD36 to 167 ± 28% and apoptosis to 183 ± 12%. These data reveal that AMPK activation plays an important role in prevention of palmitic acid-induced apoptosis and lipid accumulation in cardiomyocytes.     

Enmein Decreases Synaptic Glutamate Release and Protects against Kainic Acid-Induced Brain Injury in Rats

This study investigated the effects of enmein, an active constituent of Isodon japonicus Hara, on glutamate release in rat cerebrocortical nerve terminals (synaptosomes) and evaluated its neuroprotective potential in a rat model of kainic acid (KA)-induced glutamate excitotoxicity. Enmein inhibited depolarization-induced glutamate release, FM1-43 release, and Ca²⁺ elevation in cortical nerve terminals but had no effect on the membrane potential. Removing extracellular Ca²⁺ and blocking vesicular glutamate transporters, N- and P/Q-type Ca²⁺ channels, or protein kinase C (PKC) prevented the inhibition of glutamate release by enmein. Enmein also decreased the phosphorylation of PKC, PKC-α, and myristoylated alanine-rich C kinase substrates in synaptosomes. In the KA rat model, intraperitoneal administration of enmein 30 min before intraperitoneal injection of KA reduced neuronal cell death, glial cell activation, and glutamate elevation in the hippocampus. Furthermore, in the hippocampi of KA rats, enmein increased the expression of synaptic markers (synaptophysin and postsynaptic density protein 95) and excitatory amino acid transporters 2 and 3, which are responsible for glutamate clearance, whereas enmein decreased the expression of glial fibrillary acidic protein (GFAP) and CD11b. These results indicate that enmein not only inhibited glutamate release from cortical synaptosomes by suppressing Ca²⁺ influx and PKC but also increased KA-induced hippocampal neuronal death by suppressing gliosis and decreasing glutamate levels by increasing glutamate uptake.     

Impact resistance of fibrous glass reinforced plastics using polycarbonate‐polydimethylsiloxane block copolymer

By using reactive polydimethylsiloxanes that have phenolic hydroxyl groups at the ends of the chain, a polycarbonate‐polydimethylsiloxane (PC‐PDMS) block copolymer was prepared, and the properties of fibrous glass reinforced plastics (GF‐PC) using this copolymer were examined. The Izod impact value of the PC‐PDMS/GF composite increases with an increase in the degree of polymerization of reactive PDMS (n) between 40 and 160. When n is 40, the Izod impact value of the PC‐PDMS/GF composite is equal to that of the PC/GF composite. The Izod impact value is independent of the PDMS content of the copolymer when it is between 2 and 4 wt %. The PC‐PDMS/GF composite is superior, in the balance between fluidity and impact resistance, to the PC/GF composite. From the results of SEM, adhesion between the polymer and GF of the PC‐PDMS/GF composite is superior to that of the PC/GF composite. © 2002 Wiley Periodicals, Inc. J Appl Polym Sci 86: 1123–1127, 2002     

The Cross Talk between cGMP Signal Pathway and PKC in Pulmonary Endothelial Cell Angiogenesis

Angiogenic proliferation of vascular endothelial cells is believed to play an important role in pulmonary vascular remodeling in pulmonary arterial hypertension. In the present study, we found that c-GMP (cyclic guanosine monophosphate) inhibited the proliferation and tube formation of pulmonary vascular endothelial cells induced by TGF-β1, and that this process was reversed by PKG (protein kinase G) inhibitor and PKC (protein kinase C) inhibitor. In addition, small interfering RNA (siRNA) targeting ERK also reduced cellular proliferation. Furthermore, western blotting showed that cGMP down-regulated the phosphorylation level of ERK1/2, which was reversed not only by PKG inhibitor but also by PKC inhibitor. Silencing different PKC isoforms showed that PKCΔ, PKCγ and PKCα were involved in ERK phosphorylation, suggesting that PKC kinases have a permissive action. Three subtypes, PKCΔ, PKCγ and PKCα are likely to be involved the phosphorylation suppression of ERK included cGMP. Taken together, these data suggest that ERK phosphorylation mediates the proliferation of pulmonary vascular endothelial cells, and PKC kinases have a permissive action in this process.     

Designing a low-temperature curable phenolic/benzoxazine-functionalized phthalonitrile copolymers for high performance composite laminates

A low-temperature curable phenolic/benzoxazine-functionalized phthalonitrile (SH/BZ-CN) copolymer system with well processability is designed and applied in high performance glass fiber (GF) composite laminates. Differential scanning calorimetry (DSC) results showed that plenty of phenolic hydroxyl groups on SH could catalyze the oxazine ring-opening and triazine/phthalonitrile ring-forming reaction of BZ-CN. The ring-opening peak and ring-forming peak of SH/BZ-CN systems are reduced by 47.1 °C and 17.0 °C than those of BZ-CN, respectively. The processability of SH/BZ-CN copolymers were improved and could be controlled by tuning SH content, processing temperature and time. These parameters provided ground for preparing SH/BZ-CN/GF composite laminates under a relatively mild condition. All SH/BZ-CN/GF composite laminates exhibit excellent flexural strength more than 500 MPa and flexural modulus over 22.0 Gpa. SH/BZ-CN/GF composites showed immiscible structures and double Tgs, and they could stand high temperature up to 350 °C. Low temperature curing, short processing time and low processing pressure are beneficial to large-scale manufacturing and application of SH/BZ-CN/GF composites.     

Ether lipids inhibit the effects of phorbol diester tumor promoters

Recent studies have shown that the tumor promoter 12-O-tetradecanoyl-phorbol-13-acetate (TPA) stimulates protein kinase C (PKC), whereas the ether-linked phospholipid 1-O-octadecyl-2-O-methyl-rac-glycerol-3-phosphocholine (ET-18-OCH₃) inhibits PKC activity in vitro. Therefore, the antitumor effects of ET-18-OCH₃ could be due to its inhibition of PKC activity and the effects of tumor promotion. TPA stimulates arachidonic acid release, prostaglandin synthesis, phosphatidylcholine synthesis and the degradation of phosphatidylcholine by phospholipase C in Madin Darby canine kidney (MDCK) cells. Therefore, we have determined the effects of ET-18-OCH₃ on these consequences of TPA stimulation. Preliminary experiments determined that ET-18-OCH₃ inhibited PKC partially purified from MDCK cells by ion-exchange chromatography on DEAE-cellulose. In addition, ET-18-OCH₃, inhibited the TPA-stimulated phosphorylation of a 40,000-dalton protein in intact MDCK cells. These data indicate that ET-18-OCH₃ is an effective inhibitor of PKC activity in MDCK cells. In addition, ET-18-OCH₃ was found to inhibit arachidonic acid release and prostaglandin synthesis. The inhibition of prostaglandin synthesis appears to be secondary to inhibition of arachidonic acid release, since ET-18-OCH₃ does not inhibit TPA-stimulated synthesis of prostaglandin H synthase or the activity of the enzyme directly (Parker, J., Daniel, L. W., and Waite, M. [1987]J. Biol. Chem. 262, 5385–5393). ET-18-OCH₃ also inhibits TPA-stimulated phosphatidylcholine synthesis and phosphatidylcholine degradation by phospholipase C. These data provide evidence that the antineoplastic ether lipids inhibit the biochemical effects of the tumor promoter TPA in intact cells and indicate that this inhibition may have a role in their biological activities.